Ligand Pharma (LGND) PT Raised to $262 at RBC Capital
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.91 --0%
Rating Summary:
14 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 14
Rating Summary:
14 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 14
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $262.00 (from $252.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Lake Street Downgrades Identiv, Inc. (INVE) to Hold
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $40 at Guggenheim
- Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
